ArticleWellcome open research2023

Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.

Samuel Sang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.